CD44是大脑癌症管理的预后和治疗方法之间的联系

Linhan Cai1, Xinyu Lv2, Yiming Chen1

  • 1National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.

概括

CD44被确定为脑癌预后和治疗的关键分子. 这一发现支持了一种新的预后指数,并表明冷大气等离子体 (CAP) 是治疗脑癌的有希望的疗法.